WASHINGTON (Reuters) - An analysis by U.S. government scientists found GlaxoSmithKline Plc’s controversial diabetes drug Avandia increased heart risks and deaths compared to a rival pill, according to an email from a Food and Drug Administration reviewer who worked on the study.
